Use of aglepristone for the treatment of P4 induced insulin resistance in dogs.
10.4142/jvs.2014.15.2.267
- Author:
Enrico BIGLIARDI
1
;
Carla BRESCIANI
;
Daniela CALLEGARI
;
Francesco DI IANNI
;
Giorgio MORINI
;
Enrico PARMIGIANI
;
Ezio BIANCHI
Author Information
1. Department of Veterinary Science, University of Parma, 43100 Parma, Italy. enrico.bigliardi@gmail.com
- Publication Type:Original Article
- Keywords:
aglepristone;
bitches;
diabetes mellitus;
diestrus;
insulin resistance
- MeSH:
Animals;
Blood Glucose/analysis;
Diabetes Mellitus/drug therapy/etiology/*veterinary;
Dog Diseases/*drug therapy/etiology;
Dogs;
Estrenes/*therapeutic use;
Estrous Cycle;
Female;
Hypoglycemic Agents/therapeutic use;
Insulin Resistance;
Pregnancy;
Radioimmunoassay/veterinary;
Receptors, Progesterone/*antagonists & inhibitors
- From:Journal of Veterinary Science
2014;15(2):267-271
- CountryRepublic of Korea
- Language:English
-
Abstract:
Insulin resistance (IR) in dogs is suspected when hyperglycemia is present despite administration of insulin doses greater than 1.0 to 1.5 UI/kg. IR is caused by increases in counter regulatory hormones concentrations (glucagon, glucocorticoids, catecholamines and growth hormone). This study was conducted to investigate the use of aglepristone (RU 46534), a P4 receptor antagonist, for the treatment of IR diabetes mellitus in bitches during the luteal phase. All animals were treated with porcine insulin zinc suspension (Caninsulin) and aglepristone (Alizin) 10 mg/kg subcutaneously at day 1, 2, 9 and 17 from diagnosis. At day 5, no significant variation in glycemia was shown. At day 12 and 20, serum glucose concentrations were significant lower (p < 0.05). From day 12 the insulin dose was reduced to 0.8 IU BID. Insulin was reduced in the following weeks and glycemia was controlled.
